Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver disease

Abstract

Twenty-four-week oltipraz treatment significantly reduced the liver fat content in patients with NAFLD. Clinicaltrials.gov (NCT01373554).